H Trial Register number: NTR1683.Introduction By 2050 the amount of individuals living with dementia because of Alzheimer’s Amebae site Disease (AD) worldwide is estimated to boost from 36 million to 115 million folks [1], with two-thirds of persons affected living in creating nations. Given the worldwide public well being influence of AD, increased efforts are necessary to create novel and helpful AD interventions that happen to be easy to deploy and are certainly not resource intensive. AD can be a neurodegenerative situation Correspondence: [email protected] 1 Rush Alzheimer’s Disease Center, Rush University Healthcare Center, 600 South Paulina, Suite 1022, Chicago, IL 60612, USA Complete list of author information and facts is out there in the finish from the articleassociated with cognitive and functional capacity loss. Although the pathogenesis of AD involves the extraneuronal deposition with the amyloid-beta peptide and phosphorylation of intraneuronal tau proteins [2], loss of synapses is believed to play an important downstream part inside the process of cognitive loss [3,4]. The investigational nutrition product, Souvenaid (Nutricia N.V., Zoetermeer, the Netherlands), is often a liquid health-related meals formulation containing the certain nutrient combination, Fortasyn Connect (Nutricia N.V.). Fortasyn Connect contains nutritional precursors and cofactors for the synthesis of neuronal membranes and is developed to help synapse formation and function in individuals with AD [5]. Phosphatide molecules plus synaptic?2013 Shah et al.; licensee BioMed Central Ltd. That is an open access report distributed beneath the terms from the Inventive Commons Attribution License (creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, offered the original operate is properly cited.Shah et al. Alzheimer’s Research Therapy 2013, five:59 alzres/content/5/6/Page two ofproteins comprise the bulk of synaptic membranes and can be elevated by co-administration of rate-limiting precursors via the Kennedy pathway [6,7]. Inside a multicenter, European, randomized, double-blind, controlled proof-of-concept trial (Souvenir I), 225 drugna e sufferers with mild AD were randomized to oncedaily intake of Souvenaid or manage [8]. In this trial, delayed verbal recall score in the Wechsler Memory Scale ?revised was drastically enhanced right after 12 weeks of intervention with Souvenaid as compared with manage product. The 13-item modified Alzheimer’s Disease Assessment Scale ?Cognitive Subscale (ADAS-cog) score, the other co-primary outcome, was no diverse inside the Souvenaid group compared using the control group, but secondary analyses pointed to a potential benefit in individuals with worse baseline overall performance around the ADAS-cog [9]. Primarily based on these results, two double-blind, randomized controlled CXCR4 Storage & Stability clinical trials had been made. The Souvenir II study examined the impact of longer treatment duration (24 weeks) with Souvenaid as compared with control product on memory performance in drug-na e mild AD [10]. Because the ADAScog may perhaps be additional sensitive to modify in moderate AD [11] and since Souvenaid had not been tested in moderate AD patients currently taking AD medications, the S-Connect study was designed. In this 24-week, double-masked, parallel, randomized, controlled clinical study, the efficacy and tolerability of Souvenaid was investigated in 527 persons with mild-to-moderate AD taking stable doses of US Food and Drug Administration-approved symptomatic AD remedies (that is definitely, cholinesterase inhibitor.
